Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy and Obese Participants
NCT05712876Phase 1Completed
- Sponsor
- Cytoki Pharma
- Start
- Dec 2022
- Primary completion
- Jan 2024
- Modality
- Carrier/Scaffold Proteins, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CK-0045 in obesity (4 arms), sponsored by Cytoki Pharma. Primary endpoint: Incidence, severity and seriousness of treatment emergent adverse events. Started Dec 2022; status: completed.
02
Drugs
CK-0045
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05712876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712876.